Brooks Benard
Overview
Explore the profile of Brooks Benard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel D, Vij R, et al.
Nat Genet
. 2024 Aug;
56(9):1878-1889.
PMID: 39160255
Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The...
2.
Schwede M, Jahn K, Kuipers J, Miles L, Bowman R, Robinson T, et al.
Leukemia
. 2024 Mar;
38(7):1501-1510.
PMID: 38467769
Acute myeloid leukemia (AML) has a poor prognosis and a heterogeneous mutation landscape. Although common mutations are well-studied, little research has characterized how the sequence of mutations relates to clinical...
3.
Schwede M, Jahn K, Kuipers J, Miles L, Bowman R, Robinson T, et al.
Res Sq
. 2023 Nov;
PMID: 37986825
Acute myeloid leukemia (AML) has a poor prognosis and a heterogeneous mutation landscape. Although common mutations are well-studied, little research has characterized how the sequence of mutations relates to clinical...
4.
Zhang T, Dutta R, Benard B, Zhao F, Yin R, Majeti R
Sci Transl Med
. 2020 Apr;
12(538).
PMID: 32269167
Most patients with acute myeloid leukemia (AML) die from complications arising from cytopenias resulting from bone marrow (BM) failure. The common presumption among physicians is that AML-induced BM failure is...
5.
6.
Benard B, Gentles A, Kohnke T, Majeti R, Thomas D
Leukemia
. 2019 Feb;
33(4):826-843.
PMID: 30728456
Three mutation-specific targeted therapies have recently been approved by the FDA for the treatment of acute myeloid leukemia (AML): midostaurin for FLT3 mutations, enasidenib for relapsed or refractory cases with...